[关键词]
[摘要]
视网膜静脉阻塞( retinal vein occlusion， RVO)是临床上常见的眼底血管病，其高发性和对视力的危害性仅次于糖尿病性视网膜病变。RVO的特点是视网膜静脉扩张迂曲，沿静脉分布区域的视网膜出血、水肿和渗出，累及黄斑区时引起黄斑水肿(macular oedema， MO)，久之将导致严重的中心视力损害。RVO疾病已被命名有100多年，但是一直以来RVO引起的MO的治疗比较困难。随着治疗方法的不断推新，特别是长效皮质类固醇及近年来的抗血管内皮生长因子类药物的应用，使该病的治疗效果有了较大的改观。我们从RVO引起MO的机制、糖皮质激素和抗血管内皮生长因子药物的作用机制及治疗进展等方面进行阐述，并提出了RVO的未来治疗展望。
[Key word]
[Abstract]
Retinal vein occlusion(RVO)is the most common, vision-threatening, retinal vascular disease after diabetic retinopathy. RVO has characteristics of the retinal vein dilation and circuity, and retinal hemorrhage, edema and exudation along the vein. If edema occurs in macular area, it will lead to severe decreased central visual acuity. Though the clinical entity of RVO has been known for 100 years, the treatment remains unsatisfied. The advent of glucocorticoid and anti-vascular endothelial growth factor agents has made great progress in the treatment. The article illustrates the mechanism of macular oedema(MO)secondary to RVO. The pharmacological action and advancement of the drugs of glucocorticoid and anti-vascular endothelial growth factor agents are reviewed in this article. The prospects in the treatment of this disease are also mentioned.
[中图分类号]
[基金项目]
山东省自然科学基金(No.2R2010HM098)
